| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $34,777,622 ) (Continued on the next page) |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R03HL171172 | Developing an assessment toolkit and training for teleconsultation as an intervention to improve prehospital patient safety in children | 000 | 2 | NIH | 4/16/2025 | $147,946 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01AI167740 | Characterization of HIV-1 IgA bNAbs and ADCP function | 005 | 5 | NIH | 6/4/2025 | $266,604 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01AI167740 | Characterization of HIV-1 IgA bNAbs and ADCP function | 002 | 5 | NIH | 5/1/2025 | $807,667 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01NS128342 | Addressing an inherent bias in neuroprognostication: A collaboration between the US and Brazil to reduce the impact of Self-fulfilling Prophecy in cardiac ARrEst (SPARE) | 000 | 2 | NIH | 11/26/2024 | $532,674 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | T32MH135857 | Boston University Medical Campus- Massachusetts General Hospital Global Psychiatric Clinical Research Training Program | 001 | 2 | NIH | 6/19/2025 | $0 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | T32MH135857 | Boston University Medical Campus- Massachusetts General Hospital Global Psychiatric Clinical Research Training Program | 000 | 2 | NIH | 6/9/2025 | $420,367 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R21CA286402 | Delineating the myeloid-centric immunosuppressive crosstalk as targets for prognosis and therapy in neuroendocrine tumors | 001 | 2 | NIH | 6/11/2025 | $24,675 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R21CA286402 | Delineating the myeloid-centric immunosuppressive crosstalk as targets for prognosis and therapy in neuroendocrine tumors | 000 | 2 | NIH | 1/8/2025 | $222,077 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK138309 | Effectiveness Trial to Support Adoption of Hybrid Closed Loop Therapy in Underserved Adults with Type 1 Diabetes: Impact of System Functionality and Features on Lived Experience | 000 | 2 | NIH | 12/19/2024 | $854,975 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HD115574 | Efficacy of Teleconsultation to Improve Prehospital Patient Safety for Critically Ill Infants and Children - A Multicenter, Simulation-based Randomized Control Trial | 000 | 2 | NIH | 8/11/2025 | $748,636 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | H9E53185 | Transition for Youth with Autism and/or Epilepsy Demonstration Projects | 00 | 2 | HRSA | 7/23/2025 | $449,625 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R34DA058124 | Sustaining recovery for people on opioid agonist treatment with conversational agents | 000 | 3 | NIH | 8/22/2025 | $263,151 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K01AI167733 | Nutritional Interventions to End Tuberculosis among persons with HIV in India (NUTRIENT-India) | 000 | 3 | NIH | 9/8/2025 | $128,403 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | M0154849 | Behavioral Health Workforce Education and Training Program | 00 | 1 | HRSA | 6/18/2025 | $599,853 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | T2554939 | Addiction Medicine Fellowship | 00 | 1 | HRSA | 7/1/2025 | $799,517 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R56AI186777 | Mycobacterium tuberculosis disease effect on HIV-1 immunity, evolution, and persistence | 000 | 1 | NIH | 6/11/2025 | $711,993 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K01DK136973 | Deep learning approach for the assessment of arterial and arteriolar lesions in kidney biopsies and prediction of cardiovascular risk | 000 | 2 | NIH | 8/19/2025 | $152,273 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K01DA052821 | Perinatal care as a venue to reduce opioid overdoses and hepatitis C virus incidence (PreVenT OD HCV) | 001 | 4 | NIH | 7/17/2025 | $189,216 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HL166606 | Targeting Energetics to Improve Outcomes in Hypertrophic Cardiomyopathy | 001 | 2 | NIH | 6/26/2025 | $79,606 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HL166606 | Targeting Energetics to Improve Outcomes in Hypertrophic Cardiomyopathy | 000 | 2 | NIH | 4/22/2025 | $716,458 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01AI172843 | Antibody dependent cellular cytotoxicity and HIV-1 mother to child transmission | 001 | 4 | NIH | 9/3/2025 | $1,407,828 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HL166608 | Disease-specific risk factors for thrombosis following vascular interventions | 000 | 3 | NIH | 7/23/2025 | $678,195 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K08DA058052 | Impact of initial buprenorphine prescribing strategies on retention in care for patients with opioid use disorder | 000 | 3 | NIH | 4/7/2025 | $186,527 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K08AI166125 | Geographic origins and dispersal of drug-resistant M. tuberculosis in South Africa: Advancing strategies for early detection | 000 | 4 | NIH | 8/13/2025 | $193,752 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | D4054828 | Graduate Psychology Education Programs | 00 | 1 | HRSA | 6/11/2025 | $449,998 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DA058367 | PrEP and MOUD Rapid Access for Persons who Inject Drugs: the CHORUS+ Study | 000 | 3 | NIH | 6/18/2025 | $1,113,072 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK140570 | THRIVE-DM: Improving Diabetes Care with Strategies for Addressing Health-Related Social Needs and Community Partnerships | 000 | 2 | NIH | 7/23/2025 | $175,212 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK140570 | THRIVE-DM: Improving Diabetes Care with Strategies for Addressing Health-Related Social Needs and Community Partnerships | 000 | 2 | NIH | 7/23/2025 | $344,666 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK140570 | THRIVE-DM: Improving Diabetes Care with Strategies for Addressing Health-Related Social Needs and Community Partnerships | 001 | 2 | NIH | 8/5/2025 | $0 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK140570 | THRIVE-DM: Improving Diabetes Care with Strategies for Addressing Health-Related Social Needs and Community Partnerships | 001 | 2 | NIH | 8/5/2025 | $0 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK134616 | Significance of Tubuloglomerular Feedback in SGLT1 and SGLT2 Inhibition in Diabetic Kidney Disease | 000 | 4 | NIH | 3/21/2025 | $372,536 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | 90ZT0224 | The Moving Forward Initiative for Survivors of Torture and Their Families | 00 | 4 | ACF | 9/5/2025 | $487,341 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | S10OD038188 | Utilization of BioDot Omnia Automated Liquid Dispensing/Handling System to Enhance the Efficiency and Accuracy of High Throughput Biological Assays | 000 | 1 | NIH | 5/7/2025 | $248,756 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | S10OD038188 | Utilization of BioDot Omnia Automated Liquid Dispensing/Handling System to Enhance the Efficiency and Accuracy of High Throughput Biological Assays | 000 | 1 | NIH | 5/7/2025 | $1 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HD109005 | Investigating structural maternal health inequities among Black reproductive aged women in Georgia: a mixed methods and multi-level approach | 005 | 4 | NIH | 6/11/2025 | $2,644 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HD109005 | Investigating structural maternal health inequities among Black reproductive aged women in Georgia: a mixed methods and multi-level approach | 005 | 4 | NIH | 6/11/2025 | $461,570 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HD109005 | Investigating structural maternal health inequities among Black reproductive aged women in Georgia: a mixed methods and multi-level approach | 001 | 4 | NIH | 4/24/2025 | $468,191 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01AA030460 | Gabapentin to Reduce Alcohol and Improve Viral Load Suppression - Promoting "Treatment as Prevention" | 001 | 4 | NIH | 9/9/2025 | $125,447 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01AA030460 | Gabapentin to Reduce Alcohol and Improve Viral Load Suppression - Promoting "Treatment as Prevention" | 000 | 4 | NIH | 9/4/2025 | $550,619 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK133404 | Investigation of the role of VEGFA in harnessing cholangiocyte-driven liver regeneration | 000 | 4 | NIH | 4/23/2025 | $577,631 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01DK118267 | Nucleophosmin Centered Diagnostics and Treatment of Ischemic Acute Kidney Injury | 001 | 6 | NIH | 4/8/2025 | $471,531 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K24AT011561 | Mentoring and Patient-Oriented Research in Mind and Body Practices | 000 | 5 | NIH | 8/13/2025 | $121,371 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23NS116033 | Dynamic Risk Prediction of Life-Threatening Mass Effect After Ischemic Stroke | 001 | 5 | NIH | 5/5/2025 | $2,660 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23NS116033 | Dynamic Risk Prediction of Life-Threatening Mass Effect After Ischemic Stroke | 000 | 5 | NIH | 3/24/2025 | $216,099 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R01HL178832 | Niche-specific endothelial mechanisms regulating the extravasation of hematopoietic stem cells | 000 | 1 | NIH | 4/29/2025 | $734,607 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R03DA064474 | Immune profiling of antibodies and B cells that recognize HIV and substances in people who use substances and live with HIV (PWUSH) | 000 | 1 | NIH | 8/20/2025 | $356,630 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R25DK128858 | The Boston University Kidney and Medical Engineering Program (BU-KIDMEP) | 000 | 5 | NIH | 7/31/2025 | $122,792 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | R25DA033211 | Advancing Clinical Research Training within Addiction Residency Programs | 002 | 12 | NIH | 5/2/2025 | $366,591 |
| | 2025 | 2025 | BOSTON MEDICAL CENTER CORPORATION | 1 BOSTON MEDICAL CTR PL | BOSTON | MA | 02118-2908 | SUFFOLK | USA | K23MH128639 | Medicaid Accountable Care Organizations (ACO) and Quality of Care for Adults with Serious Mental Illness (SMI) | 000 | 4 | NIH | 3/13/2025 | $189,432 |
|
